KAILERA IPO
US market today: Biotech firm Odyssey hits nearly $900 million valuation as shares rise in Nasdaq debutOdyssey Therapeutics debuted on Nasdaq with an 11.1% surge, reaching a $899.9 million valuation. The autoimmune disease specialist successf...
US Stocks | Kailera soars over 60% in Nasdaq debut as weight-loss drug race heats upKailera Therapeutics shares surged 62.5% in their Nasdaq debut after raising $625 million in a U.S. IPO priced at the top end of its range....
US IPO hopefuls forge ahead with listing plans amid market swingsCompanies across sectors have resumed IPO roadshows despite Middle East tensions, signalling pent-up demand in the pipeline. Analysts expec...
- Load More